Latest News — Page 2

Drug Pricing
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%
A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.

Cost Effectiveness Analysis
The EU HTA Regulation: What Latin America Can Learn
A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.

Artificial Intelligence And Machine Learning
Artificial Intelligence in Medicine Regulation: From Concept to Practice
EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation

Europe Free account
EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027
The European Medicines Agency has opened public consultation on its draft guideline on predictive biomarker assays. Comments are accepted from 9 November 2026 until 31 March 2027.

Clinical Practice
FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists
FDA is requiring every GLP-1 receptor agonist label to carry a warning on NAION, a rare eye condition that can cause permanent vision loss. #SyenzaNews #drugsafety #GLP1

Cardiovascular And Metabolic Diseases
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess

Cost Effectiveness Analysis
Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up
Law 3563 creates a Neuquén health technology assessment agency. Guadalupe Montero explains how it will weigh safety, benefit, equity and budget impact.

Clinical Guidelines And Protocols Free account
Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November
The Enzutrix patent dispute goes to South Africa’s Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess

Health Policy Free account
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess

Health Policy
Medicare drug price negotiation: CMS sets permanent rules
The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess

Clinical Practice
Zepbound and Foundayo telehealth access via Hims & Hers
Eli Lilly and Hims & Hers Health agreed to widen Zepbound and Foundayo telehealth access, with self-pay prices starting at $149 per month. #SyenzaNews #obesity #telehealth

Asia
M72 tuberculosis vaccine approval in Indonesia: BPOM weighs a fast track
BPOM is drafting a conditional approval route for the M72 TB vaccine and a joint review with the European Medicines Agency, ahead of Phase 3 results.

Cost Effectiveness Analysis Free account
Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B
INFARMED recommends public funding for Refixia nonacog beta pegol in children under 12 with haemophilia B, based on two single-arm trials. #SyenzaNews #MarketAccess

Clinical Practice
Recent Zolgensma safety concerns: what Novartis has reported
SMA Europe has relayed Novartis’s figures on tumour reports in patients previously treated with Zolgensma, including two cases of vector DNA integration.

Cost Effectiveness Analysis Free account
Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit
The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.

Artificial Intelligence And Machine Learning Free account
State AI Liability in Health Care: Lawsuits Test Insurers, Apps and Chatbots
A Congressional Research Service sidebar maps the state lawsuits over AI in health care, from insurer claim denials to wellness apps and chatbots.
